FDA Clears a New Class of Myeloma Drug for Patients Whose Cancer Returned After Earlier Treatment

The FDA granted accelerated approval to iberdomide, the first CELMoD for relapsed multiple myeloma, usable as early as first relapse.

Have A Referral?